Stefan Deneberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8085343/publications.pdf

Version: 2024-02-01

		686830	525886
32	774	13	27
papers	citations	h-index	g-index
32	32	32	1539
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia. Leukemia, 2010, 24, 932-941.	3.3	113
2	Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritisa randomized study. Journal of Rheumatology, 2007, 34, 1810-6.	1.0	85
3	Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by <i>DNMT3A</i> mutational status and associated with predominant hypomethylation of HOX genes. Epigenetics, 2014, 9, 1108-1119.	1.3	74
4	Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. Blood, 2011, 118, 5573-5582.	0.6	67
5	Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia, 2021, 35, 62-74.	3.3	63
6	APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells. European Journal of Haematology, 2011, 86, 206-215.	1.1	61
7	The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. Blood Advances, 2020, 4, 1094-1101.	2.5	44
8	<i>microRNA-34b/c</i> on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia. Epigenetics, 2014, 9, 910-917.	1.3	43
9	Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. Blood, 2019, 134, 1558-1561.	0.6	38
10	The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2008, 62, 439-448.	1.1	32
11	Acute myeloid leukemia in very old patients. Haematologica, 2018, 103, e578-e580.	1.7	17
12	AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding. Blood, 2020, 136, 339-352.	0.6	17
13	Single nucleotide polymorphism genomic arrays analysis of t(8;21) acute myeloid leukemia cells. Haematologica, 2009, 94, 1301-1306.	1.7	16
14	Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: A populationâ€based study from the Swedish AML registry. European Journal of Haematology, 2017, 98, 493-500.	1.1	14
15	Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI. Leukemia, 2021, 35, 2416-2418.	3.3	13
16	A risk score based on real-world data to predict early death in acute promyelocytic leukemia. Haematologica, 2022, 107, 1528-1537.	1.7	12
17	Realâ€world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥Â60Âyears. British Journal of Haematology, 2020, 189, e13-e16.	1.2	10
18	Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation. Oncology Reports, 2009, 22, 137-42.	1.2	7

STEFAN DENEBERG

#	Article	IF	CITATIONS
19	Decreasing early mortality in acute myeloid leukaemia in Sweden 1997–2014: improving performance status is a major contributing factor. British Journal of Haematology, 2020, 188, 187-191.	1.2	7
20	Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with <scp><i>BCR</i>â€<i>ABL1</i></scp> , a Swedish populationâ€based study. Genes Chromosomes and Cancer, 2021, 60, 426-433.	1.5	7
21	Epigenetics in Myeloid Malignancies. Methods in Molecular Biology, 2012, 863, 119-137.	0.4	7
22	Expression of p14ARF in De Novo AML with Normal Karyotype. Implication on Drug Resistance and Survival Blood, 2007, 110, 4261-4261.	0.6	6
23	Relapse of preB-ALL after rituximab treatment for chronic graft versus host disease. Implications for its use?. Medical Oncology, 2007, 24, 354-356.	1.2	5
24	A Combination Regimen of Bortezomib, Cyclophosphamide and Betamethasone Gives Quicker, Better and More Durable Response than VAD/CyBet Regimens: Results from a Swedish Retrospective Analysis. Acta Haematologica, 2013, 130, 7-15.	0.7	5
25	Low p14ARF expression inde novoacute myeloid leukemia with normal karyotype is associated with poor survival. Leukemia and Lymphoma, 2009, 50, 1512-1518.	0.6	4
26	ls there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study. Leukemia and Lymphoma, 2021, 62, 1973-1981.	0.6	4
27	Genome-Wide DNA Methylation Analysis Shows Enrichment of Differential Methylation in "Open Seas― and Enhancers and Reveals Hypomethylation in DNMT3A Mutated Cytogenetically Normal AML (CN-AML). Blood, 2012, 120, 653-653.	0.6	3
28	Different Incidence and Implications of DNA Hypermethylation in De Novo AML Compared to High-Risk MDS and AML Following MDS Blood, 2008, 112, 3337-3337.	0.6	0
29	In Vitro and Ex Vivo Studies On Cell Lines and Primary Human Leukemia Cells of the Effects of APR-246 Alone and in Combination with Conventional Chemotherapeutic Drugs Blood, 2009, 114, 2751-2751.	0.6	0
30	Global and HOX Gene DNA Methylation In Normal Karyotype Acute Myeloid Leukemia: Clinical Implications and Molecular Correlations. Blood, 2010, 116, 231-231.	0.6	0
31	Reasons for Decreasing Early Mortality in Acute Myeloid Leukemia: An Epidemiological Study from the Swedish Acute Leukemia Registry. Blood, 2015, 126, 3748-3748.	0.6	0
32	Phenotypic and Functional Alterations of Bone Marrow Mesenchymal Stem and Progenitor Cells in Chronic Myeloid Leukemia. Blood, 2015, 126, 2398-2398.	0.6	0